Literature DB >> 20484214

Withdrawal symptoms after gabapentin discontinuation.

Thaddaus R Hellwig1, Rhonda Hammerquist, Jill Termaat.   

Abstract

PURPOSE: A case of apparent gabapentin withdrawal symptoms after discontinuation of gabapentin therapy is reported.
SUMMARY: A 53-year-old woman had coffee ground emesis, a two-day history of black tarry stools, and abdominal pain. The patient did have an elevated ethanol concentration (323 mg/dL), with the last reported ingestion of ethanol about 12 hours before admission. Her medical history included liver cirrhosis secondary to ethanol abuse, ascites, portal hypertension, esophageal varices (with previous band ligation three weeks prior), anemia, gastroesophageal reflux disease, neuropathic pain, and depression. Her home medications included spironolactone, nadolol, lactulose, ursodiol, ferrous sulfate, omeprazole, gabapentin, citalopram, and trazodone. She was admitted to the intensive care unit, and upper gastrointestinal endoscopy was performed, with 12 band ligations applied. After the procedure, she ingested nothing orally, including home medications, for the first two days. On day 3 of hospitalization, she developed restlessness, disorientation, confusion, agitation, and anxiety. She was presumed to be suffering from ethanol withdrawal and was treated with benzodiazepines but had no improvement in symptoms. During days 4 and 5, the patient became increasingly confused, agitated, and anxious, with complaints of headache, light sensitivity, and increasing nervousness. On day 5, gabapentin was reinitiated, and the patient's confusion and agitation improved that evening. The next morning, the patient was calm, alert, and cooperative. Her symptoms resolved, and she was discharged on hospital day 7.
CONCLUSION: A patient developed apparent withdrawal symptoms beginning two days after gabapentin therapy was discontinued. The symptoms were unresponsive to treatment with benzodiazepines but completely resolved with the reinitiation of gabapentin therapy.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20484214     DOI: 10.2146/ajhp090313

Source DB:  PubMed          Journal:  Am J Health Syst Pharm        ISSN: 1079-2082            Impact factor:   2.637


  11 in total

Review 1.  Abuse and Misuse of Pregabalin and Gabapentin.

Authors:  Kirk E Evoy; Megan D Morrison; Stephen R Saklad
Journal:  Drugs       Date:  2017-03       Impact factor: 9.546

2.  Abuse of combinations of gabapentin and quetiapine.

Authors:  Roy R Reeves; Randy S Burke
Journal:  Prim Care Companion CNS Disord       Date:  2014-09-11

Review 3.  Drug deprescription-withdrawal risk, prevention, and treatment.

Authors:  Madison K Bangert; Gabriel M Aisenberg
Journal:  Proc (Bayl Univ Med Cent)       Date:  2019-12-20

4.  Randomized, placebo-controlled pilot trial of gabapentin during an outpatient, buprenorphine-assisted detoxification procedure.

Authors:  Nichole C Sanders; Michael J Mancino; W Brooks Gentry; J Benjamin Guise; Warren K Bickel; Jeff Thostenson; Alison H Oliveto
Journal:  Exp Clin Psychopharmacol       Date:  2013-07-15       Impact factor: 3.157

5.  All-Cause and Drug-Related Medical Events Associated with Overuse of Gabapentin and/or Opioid Medications: A Retrospective Cohort Analysis of a Commercially Insured US Population.

Authors:  Alyssa M Peckham; Kathleen A Fairman; David A Sclar
Journal:  Drug Saf       Date:  2018-02       Impact factor: 5.606

6.  Current diagnosis and treatment of anxiety disorders.

Authors:  Alexander Bystritsky; Sahib S Khalsa; Michael E Cameron; Jason Schiffman
Journal:  P T       Date:  2013-01

Review 7.  Gabapentin misuse, abuse and diversion: a systematic review.

Authors:  Rachel V Smith; Jennifer R Havens; Sharon L Walsh
Journal:  Addiction       Date:  2016-03-18       Impact factor: 6.526

8.  Gabapentin Prevents Progressive Increases in Excitatory Connectivity and Epileptogenesis Following Neocortical Trauma.

Authors:  D K Takahashi; Sha Jin; D A Prince
Journal:  Cereb Cortex       Date:  2018-08-01       Impact factor: 5.357

9.  Prevalence of Gabapentin Abuse: Comparison with Agents with Known Abuse Potential in a Commercially Insured US Population.

Authors:  Alyssa M Peckham; Kathleen A Fairman; David A Sclar
Journal:  Clin Drug Investig       Date:  2017-08       Impact factor: 2.859

10.  Dispensations of benzodiazepines, z-hypnotics, and gabapentinoids to patients receiving opioid agonist therapy; a prospective cohort study in Norway from 2013 to 2017.

Authors:  Jørn Henrik Vold; Svetlana Skurtveit; Christer Aas; Fatemeh Chalabianloo; Pia Synnøve Kloster; Kjell Arne Johansson; Lars Thore Fadnes
Journal:  BMC Health Serv Res       Date:  2020-04-25       Impact factor: 2.655

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.